Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.

Details

Serval ID
serval:BIB_0968A9F9CD4C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Journal
Cancers
Author(s)
Chiang C.L., Rovelli R., Sarivalasis A., Kandalaft L.E.
ISSN
2072-6694 (Print)
ISSN-L
2072-6694
Publication state
Published
Issued date
10/09/2021
Peer-reviewed
Oui
Volume
13
Number
18
Pages
4553
Language
english
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Abstract
As the majority of ovarian cancer (OC) patients are diagnosed with metastatic disease, less than 40% will survive past 5 years after diagnosis. OC is characterized by a succession of remissions and recurrences. The most promising time point for immunotherapeutic interventions in OC is following debulking surgery. Accumulating evidence shows that T cells are important in OC; thus, cancer vaccines capable of eliciting antitumor T cells will be effective in OC treatment. In this review, we discuss different cancer vaccines and propose strategies for their incorporation into the OC standard-of-care regimens. Using the murine ID8 ovarian tumor model, we provide evidence that a cancer vaccine can be effectively combined with OC standard-of-care to achieve greater overall efficacy. We demonstrate several important similarities between the ID8 model and OC patients, in terms of response to immunotherapies, and the ID8 model can be an important tool for evaluating combinatorial regimens and clinical trial designs in OC. Other emerging models, including patient-derived xenograft and genetically engineered mouse models, are continuing to improve and can be useful for evaluating cancer vaccination therapies in the near future. Here, we provide a comprehensive review of the completed and current clinical trials evaluating cancer vaccines in OC.
Keywords
antitumor responses, cancer vaccines, combinatorial immunotherapy strategies, ovarian cancer, tumor microenvironment
Pubmed
Web of science
Open Access
Yes
Create date
04/10/2021 10:24
Last modification date
13/10/2021 5:43
Usage data